Side-by-Side Comparison
Epithalon vs NAD+: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how Epithalon and NAD+ differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Also: Epitalon, Epithalone, AEDG peptide
A tetrapeptide studied for its potential to activate telomerase and extend cellular lifespan, primarily in Russian research.
NAD+
L3Also: Nicotinamide Adenine Dinucleotide, NAD
A coenzyme critical for cellular energy and DNA repair. Not technically a peptide, but commonly discussed alongside peptide therapies in the longevity space.
Side-by-side comparison
| Attribute | Epithalon | NAD+ |
|---|---|---|
| Primary mechanism | Telomerase Activation | Sirtuin & PARP Cofactor |
| FDA status | Research Only | Research Only |
| Evidence level | Preclinical Evidence | Emerging Clinical Evidence |
| Human trials | Yes (2+ indexed) | Yes (20+ indexed) |
| Studies indexed | 33 total (3 human, 18 animal) | 260 total (15 human, 85 animal) |
| Primary uses researched | Telomerase activation, Anti-aging, Cellular longevity | Cellular energy, DNA repair, Anti-aging, Neuroprotection, Addiction recovery (anecdotal) |
| Administration routes | subcutaneous | intravenous, oral, sublingual |
| Molecular weight | 390.35 Da | 663.43 Da |
| Amino acids | 4 | — |
| Category | longevity anti aging | longevity anti aging |
| WADA status | Permitted | Permitted |
Key differences
Mechanism. Epithalon acts primarily through telomerase activation, while NAD+ acts primarily through sirtuin & parp cofactor. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Both compounds share the same FDA status (Research Only), which means the practical pathway to access is similar for each.
Evidence base. NAD+ sits at a higher evidence level (L3) than Epithalon (L2) under PeptideMark's L1–L5 methodology.
Research focus. Published research on Epithalon has concentrated on telomerase activation, anti-aging, cellular longevity. Research on NAD+ has concentrated on cellular energy, dna repair, anti-aging. There is meaningful overlap between the two research programs, which is why these compounds are frequently compared.
Safety snapshot
| Attribute | Epithalon | NAD+ |
|---|---|---|
| Documented effects | 4 total | 6 total |
| Serious events | 0 | 0 |
| Common events | 1 | 2 |
| Black box warning | No | No |
| Contraindications | 3 listed | 3 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions (SC/IV) |
Strengths & limitations
Epithalon
Strengths
- Not on the WADA prohibited list
Limitations
- Not FDA-approved for any indication — research use only
- Limited evidence base (L2)
- Few human trials — most data is preclinical
NAD+
Strengths
- Multiple human clinical trials (20+ indexed)
- Not on the WADA prohibited list
Limitations
- Not FDA-approved for any indication — research use only
Representative studies
Epithalon
Peptide promotes telomere elongation in human cells
Khavinson VK, et al. · Bulletin of Experimental Biology and Medicine (2003)
Epithalon induced telomerase activity in human pulmonary fibroblasts and increased telomere length by 33%.
PubMed 14612619Epithalon (Epitalon) Increases Telomerase Activity and Extends Lifespan in Telomerase-Deficient Mice
Dilman VM, Anisimov VN. · Mechanisms of Ageing and Development (1999)
Epithalon restored telomerase activity in bone marrow and thymus; increased median lifespan by 16% and maximum lifespan by 11%.
PubMed 10614941NAD+
NAD+ metabolism and its roles in cellular processes during ageing
Covarrubias AJ, et al. · Nature Reviews Molecular Cell Biology (2021)
NAD+ levels decline with age across species, and restoring NAD+ has shown benefits in animal models for multiple aging-related conditions.
PubMed 33353981NMN supplementation improves metabolic and mitochondrial function in aged mice
Cantó C, Houtkooper RH, Pirinen E, et al. · Cell Metabolism (2012)
NMN restored muscle NAD+ to youthful levels; improved VO2max by 29% and exercise capacity by 56% in aged mice.
PubMed 22326221Frequently asked
What is the main difference between Epithalon and NAD+?
Epithalon is a tetrapeptide studied for its potential to activate telomerase and extend cellular lifespan, primarily in russian research. Its primary mechanism is telomerase activation. NAD+ is a coenzyme critical for cellular energy and dna repair. not technically a peptide, but commonly discussed alongside peptide therapies in the longevity space. Its primary mechanism is sirtuin & parp cofactor. The two differ in regulatory status (Research Only vs Research Only), strength of evidence (L2 vs L3), and the primary conditions for which each is researched.
Is Epithalon or NAD+ FDA approved?
Epithalon: Not FDA-approved. Research compound only. Not on Category 2 list. Primarily studied in Russian research institutions. NAD+: NAD+ itself is not FDA-approved as a drug. Precursors (NMN, NR) are sold as supplements. IV NAD+ is offered at clinics but not FDA-regulated.
How does the evidence base compare?
Epithalon has 33 indexed studies (3 human, 18 animal) and is rated Preclinical Evidence. NAD+ has 260 indexed studies (15 human, 85 animal) and is rated Emerging Clinical Evidence. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can Epithalon and NAD+ be compared directly?
Yes — both compounds share the longevity anti aging category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are Epithalon and NAD+ commonly stacked together?
There is no widely documented stacking protocol combining Epithalon and NAD+ in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, Epithalon or NAD+?
Epithalon has 4 documented side effects (0 serious). NAD+ has 6 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are Epithalon and NAD+ administered?
Epithalon is typically administered via subcutaneous. NAD+ is typically administered via intravenous or oral or sublingual. Route differences affect onset, peak levels, and patient convenience.
Which is better, Epithalon or NAD+?
"Better" depends on the therapeutic goal, regulatory context, and individual response. Epithalon is most researched for telomerase activation and anti-aging; NAD+ is most researched for cellular energy and dna repair. FDA status also matters: Research Only for Epithalon vs Research Only for NAD+. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
Epithalon →
Full profile
NAD+ →